4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Robot Cookies – Plant Cell Packs as an Automated High-Throughput Screening Platform Based on Transient Expression

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The high-throughput screening of recombinant protein expression is advantageous during early process development because it allows the identification of optimal expression constructs and process conditions. Simple screening platforms based on microtiter plates are available for microbes and animal cells, but this was not possible for plants until the development of plant cell packs (PCPs), also known as “cookies,” which provide a versatile and scalable screening tool for recombinant protein production. PCPs are prepared from plant cell suspension cultures by removing the medium and molding the biomass. PCPs can be cast into 96-well plates for high-throughput screening, but the manual handling effort currently limits the throughput to ∼500 samples per day. We have therefore integrated the PCP method with a fully automated laboratory liquid-handling station. The “robot cookies” can be prepared and infiltrated with Agrobacterium tumefaciens by centrifugation, minimizing operator handling and reducing the likelihood of errors during repeated runs, such as those required in a design of experiments approach. The accumulation of fluorescent protein in the cytosol, apoplast, endoplasmic reticulum or plastids is easily detected using an integrated plate reader, reducing the inter-experimental variation to <5%. We also developed a detergent-based chemical lysis method for protein extraction in a 96-well format, which was adapted for automated downstream processing using miniaturized columns allowing subsequent protein analysis. The new automated method reduces the costs of the platform to <0.5 € per PCP infiltration (a saving of >50%) and facilitates a five-fold increase in throughput to >2500 samples per day.

          Related collections

          Most cited references55

          • Record: found
          • Abstract: found
          • Article: not found

          Tempo and mode of genome evolution in a 50,000-generation experiment

          Adaptation by natural selection depends on the rates, effects, and interactions of many mutations, making it difficult to determine what proportion of mutations in an evolving lineage are beneficial. We analysed 264 complete genomes from 12 Escherichia coli populations to characterize their dynamics over 50,000 generations. The populations that retained the ancestral mutation rate support a model where most fixed mutations are beneficial, the fraction of beneficial mutations declines as fitness rises, and neutral mutations accumulate at a constant rate. We also compared these populations to mutation-accumulation lines evolved under a bottlenecking regime that minimizes selection. Nonsynonymous mutations, intergenic mutations, insertions, and deletions are overrepresented in the long-term populations, further supporting the inference that most mutations that reached high frequency were favoured by selection. These results illuminate the shifting balance of forces that govern genome evolution in populations adapting to a new environment.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            NON-NORMALITY AND TESTS ON VARIANCES

            G. BOX (1953)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives

              Abstract Biotherapeutic proteins represent a mainstay of treatment for a multitude of conditions, for example, autoimmune disorders, hematologic disorders, hormonal dysregulation, cancers, infectious diseases and genetic disorders. The technologies behind their production have changed substantially since biotherapeutic proteins were first approved in the 1980s. Although most biotherapeutic proteins developed to date have been produced using the mammalian Chinese hamster ovary and murine myeloma (NS0, Sp2/0) cell lines, there has been a recent shift toward the use of human cell lines. One of the most important advantages of using human cell lines for protein production is the greater likelihood that the resulting recombinant protein will bear post-translational modifications (PTMs) that are consistent with those seen on endogenous human proteins. Although other mammalian cell lines can produce PTMs similar to human cells, they also produce non-human PTMs, such as galactose-α1,3-galactose and N-glycolylneuraminic acid, which are potentially immunogenic. In addition, human cell lines are grown easily in a serum-free suspension culture, reproduce rapidly and have efficient protein production. A possible disadvantage of using human cell lines is the potential for human-specific viral contamination, although this risk can be mitigated with multiple viral inactivation or clearance steps. In addition, while human cell lines are currently widely used for biopharmaceutical research, vaccine production and production of some licensed protein therapeutics, there is a relative paucity of clinical experience with human cell lines because they have only recently begun to be used for the manufacture of proteins (compared with other types of cell lines). With additional research investment, human cell lines may be further optimized for routine commercial production of a broader range of biotherapeutic proteins.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Bioeng Biotechnol
                Front Bioeng Biotechnol
                Front. Bioeng. Biotechnol.
                Frontiers in Bioengineering and Biotechnology
                Frontiers Media S.A.
                2296-4185
                05 May 2020
                2020
                : 8
                : 393
                Affiliations
                [1] 1Fraunhofer Institute for Molecular Biology and Applied Ecology IME , Aachen, Germany
                [2] 2Institute for Molecular Biotechnology, RWTH Aachen University , Aachen, Germany
                Author notes

                Edited by: Pau Ferrer, Autonomous University of Barcelona, Spain

                Reviewed by: Sylvain Legay, Luxembourg Institute of Science and Technology, Luxembourg; Kirsi-Marja Oksman-Caldentey, VTT Technical Research Centre of Finland Ltd., Finland

                *Correspondence: Johannes Felix Buyel, johannes.buyel@ 123456rwth-aachen.de

                This article was submitted to Bioprocess Engineering, a section of the journal Frontiers in Bioengineering and Biotechnology

                Article
                10.3389/fbioe.2020.00393
                7214789
                32432097
                339ba837-3e03-4555-a433-437f8da4dbc3
                Copyright © 2020 Gengenbach, Opdensteinen and Buyel.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 05 March 2020
                : 08 April 2020
                Page count
                Figures: 7, Tables: 2, Equations: 5, References: 69, Pages: 15, Words: 0
                Funding
                Funded by: Fraunhofer-Gesellschaft 10.13039/501100003185
                Funded by: Ministerium für Innovation, Wissenschaft und Forschung des Landes Nordrhein-Westfalen 10.13039/501100009591
                Funded by: Deutsche Forschungsgemeinschaft 10.13039/501100001659
                Categories
                Bioengineering and Biotechnology
                Original Research

                agrobacterium tumefaciens,automated transient expression,design of experiments,plant molecular farming,rapid protein synthesis,small-scale production

                Comments

                Comment on this article